Drugs / ONP-002
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT06870240 Comparator | Jun 2025 → Jan 2026 overdue | traumatic brain injury | Oragenics, Inc. | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ONP-002 | “ONP-002 is 8mg API and 92 Hydroxy-propyl beta-cyclodextrin as a spray-dried powder” NCT06870240 ↗ |
| Modality | Small molecule | “A non-natural synthetic neurosteroid enantiomer considered a new chemical entity” NCT06870240 ↗ |
| Route | Intranasal | “through IN administration” NCT06870240 ↗ |